Immunicum: Positive Safety Update from ILIAD Combination Trial
Redeye believes the update from the ILIAD trial confirms the strong safety profile of ilixadencel, notably now also in combination with checkpoint inhibitors. While we have to wait a bit longer for a full update, including, e. g. , efficacy data, we expect a positive reaction to the news.